
Betty Diamond
Investigator and Head of the Center for Autoimmune and Musculoskeletal Disease · University of Washington School of Medicine
Credentials: · ·
History
PresentCenter for Autoimmune and Musculoskeletal Disease Division · University of Washington School of Medicine

Rheumatology
Internal Medicine
Research
The gut microbiota influences blood-brain barrier permeability in mice
Science Translational Medicine · 2014 · 1,929 citations
Arthritis & Rheumatology · 2019 · 1,900 citations
Combined oral contraceptives in women with systemic lupus erythematosus
New England Journal of Medicine · 2005 · 895 citations

109 papers
- AS
109 papers · 30 as a resident

109 papers · 96 as a fellow
- DL
109 papers
- GS
109 papers

109 papers · 49 as a resident
- PL
109 papers
- PS
109 papers
Grants
- 2026–2031
T32 Medical Scientist Training Program (MSTP) at the Zucker School of Medicine at Hofstra/Northwell
National Institute of General Medical Sciences · T32
Contact PI · $355K · Hofstra University
- 2021–2031
Cellular Cross-Talk in Autoimmune Disease
National Institute of Allergy and Infectious Diseases · P01
Project lead · $3.6M · Brigham and Women's Hospital
- 2008–2030
Anti-NMDA Receptor Antibodies in Adult Brain Dysfunction: Lessons from Lupus
National Institute of Allergy and Infectious Diseases · P01
Contact PI · $43.3M · Feinstein Institute for Medical Research
- 2024–2029
Learning from Remission and Relapse in SLE
National Institute of Allergy and Infectious Diseases · P01
Contact PI · $8.7M · Feinstein Institute for Medical Research
Clinical trials
- 2008–2014
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
Principal investigator · Completed · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
- 2023–2025
Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA
Study chair · Terminated · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
- 2022–2028
VIBRANT: VIB4920 for Active Lupus Nephritis
Study chair · Recruiting · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
- 2015–2019
Rituximab and Belimumab for Lupus Nephritis
Study chair · Completed · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
